Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer

The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.

Trial Details

NCT ID
NCT06052098
Phase
NA
Sponsor
Hangzhou Broncus Medical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system
  • The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age greater than 18 years.
  • Primary peripheral lung cancer diagnosed by pathology, and preoperative staging reveals clinical stage T1N0M0, stage IA.
  • The planned ablation lesions are assessed to be amenable to CT-guided and bronchoscopy-guided ablation.
  • Assessed as inoperable or refused surgery, agree to undergo initial ablation therapy, and sign informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →